Company intelligence / Profile preview

Oncodea

Saint Paul, Minnesota, United Statesoncodea.com ↗

Ownership: Private
Development stage: Other

Overview

The company has developed a non-invasive blood test using nano-enhanced IR sensing and AI to detect universal molecular fingerprints of various cancers from small blood samples. The technology aims for high accuracy at low cost but has not yet reported clinical trial outcomes.

Therapeutic areas: Oncology
Modalities: Nanoparticle-enhanced infrared molecular sensing (nano-IR)Artificial intelligence-based diagnostics platform (OncodeAi™)Blood-based biomarker detection (liquid biopsy)
Industry: Metabolite Diagnostics

Partnerships

None publicly disclosed as of June 2025.

Beyond the preview

Go deeper on Oncodea.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Oncodea.

Explore the full profile